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Rapamycin-Eluting Stent Evaluated At
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oost Daemen,* Ruud A. M. Erdman, PHD,*† Pieter C. Smits, MD, PHD,*
atrick W. J. C. Serruys, MD, PHD, FESC, FACC,* Ron T. van Domburg, PHD*
otterdam and Tilburg, The Netherlands
OBJECTIVES We investigated the effect of Type D personality on the occurrence of adverse events at
nine months in patients with ischemic heart disease (IHD) after percutaneous coronary
intervention (PCI) with sirolimus-eluting stents (SESs) or bare stents. Type D patients
experience increased negative emotions and tend not to express these emotions in social
interactions.
BACKGROUND The SES is a new advent in interventional cardiology that reduces the restenosis rate and the
risk of a major adverse cardiac event, but the SES has not been shown to confer any benefits
on death or myocardial infarction (MI).
METHODS Consecutive patients with IHD (n  875) enrolled in the Rapamycin-Eluting Stent
Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry completed the Type D
Personality Scale (DS14) six months after PCI. The end point was a composite of death and
MI. Events occurring before administration of the DS14 were excluded from analyses.
RESULTS At nine months’ follow-up, there were 20 events. Type D patients were at a cumulative
increased risk of adverse outcome compared with non-Type D patients: 5.6% versus 1.3% (p
 0.002). Type D personality (odds ratio [OR] 5.31; 95% confidence interval [CI] 2.06 to
13.66) remained an independent predictor of adverse outcome adjusting for all other variables,
including SES versus bare-stent implantation.
CONCLUSIONS Type D personality was an independent predictor of adverse events in patients optimally
treated with the latest advent in interventional cardiology. The DS14 could be used as a
screening instrument in routine clinical practice to optimize risk stratification in IHD
patients. (J Am Coll Cardiol 2004;44:997–1001) © 2004 by the American College of
Cardiology Foundationo
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dhe effectiveness of percutaneous coronary intervention
PCI) in patients with ischemic heart disease (IHD) has
mproved considerably since the procedure was first intro-
uced in the late 1970s (1). Nevertheless, in-stent restenosis
as remained as the major limitation hampering the clinical
fficacy of percutaneous revascularization. With the intro-
uction of drug-eluting stents, the incidence of restenosis
as decreased significantly compared with conventional
tenting, reducing the need for repeat revascularization
anging from 59% and higher in selected patients (2,3).
rug-eluting stents have not been shown to decrease the
ncidence of death or myocardial infarction (MI), and in this
ew “restenosis-free” era following PCI, therefore, there is
till a need to identify subgroups at increased risk of death
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Department of Psychology and Health, Tilburg University, Tilburg, The Nether-
ands. This study was supported by the Erasmus Medical Center, Rotterdam, The
etherlands, and by Cordis, a Johnson & Johnson Company, Miami Lakes, Florida.
Manuscript received March 10, 2004; revised manuscript received April 23, 2004;tccepted May 18, 2004.r MI. This may warrant the examination of nontraditional
isk factors, such as psychological risk factors, in addition to
he established biomedical risk factors.
From the pre-drug-eluting stent era, there is evidence to
uggest that emotionally distressed patients comprise one
ubgroup that does not benefit optimally after cardiac
nvasive treatment. Depression has been associated with a
ore than two-fold increased risk of a recurrent cardiac
vent after coronary artery bypass graft surgery (CABG)
4,5). Prior history of depression and vital exhaustion have
een shown to lead to adverse clinical outcomes in patients
fter PCI (6,7).
Patients with a Type D or distressed personality form
nother subgroup that is at risk of inadequate response to
reatment. Type D personality has been shown to indepen-
ently predict adverse clinical outcome in IHD, and the
rognostic power of the Type D personality equals that of
eft ventricular dysfunction (8–10). Type D personality
efines individuals who experience increased negative emo-
ions and who do not express these emotions in social
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Type D and Prognosis After PCI September 1, 2004:997–1001nteractions (9). To date, no study has investigated the
mpact of Type D personality on the prognosis of patients
reated with PCI in the drug-eluting stent era.
The objective of this study was to investigate the impact
f Type D personality on prognosis at nine months’
ollow-up in consecutive unselected IHD patients treated
ith either sirolimus-eluting stents (SESs) or bare stents.
ETHODS
tudy design and patient population. Since April 2002,
he SES (Cypher; Johnson & Johnson–Cordis unit, Cordis
uropa NV, Roden, The Netherlands) has been utilized as
he device of choice for all patients treated with PCI in our
nstitution, as part of the Rapamycin-Eluting Stent Evalu-
ted At Rotterdam Cardiology Hospital (RESEARCH)
egistry (11,12). The study protocol of this registry has been
escribed elsewhere (12). Briefly, it is a single-center study
hat evaluates the impact of unrestricted SES implantation
n the clinical outcomes of patients treated in the “real
orld” of interventional cardiology. To accomplish this
bjective, all patients treated with PCI were considered for
nrollment regardless of anatomical or clinical presentation.
or comparison, a control group was composed of all
onsecutive patients treated with conventional percutaneous
echniques in the period immediately before the introduc-
ion of the SES.
In both study phases, patients were prospectively followed
p for clinical adverse events. Additionally, all living pa-
ients were contacted at six months to complete a question-
aire that evaluates the presence of Type D personality.
etween October 2001 and October 2002 (six-month
nrollment in each study phase), a total of 1,237 patients
ere treated with pure bare stents or pure SES; of these, 875
atients (71%) (SES: n  358; bare stents: n  517)
eturned the questionnaire.
Nonresponders were younger and more likely to have had
previous MI, to suffer from diabetes, or to be treated with
ngiotensin-converting enzyme (ACE) inhibitors. They
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CABG  coronary artery bypass graft surgery
CI  confidence interval
CK  creatine kinase
IHD  ischemic heart disease
MI  myocardial infarction
NA  negative affectivity
OR  odds ratio
PCI  percutaneous coronary intervention
RESEARCH  Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital registry
SES  sirolimus-eluting stent
SI  social inhibition
TIMI  Thrombolysis In Myocardial Infarction
TNF  tumor necrosis factorere less likely to suffer from renal impairment or to be created with aspirin and beta-blockers (p  0.05). No other
tatistically significant differences were found between re-
ponders and nonresponders on baseline characteristics.
thical approval was obtained from the hospital ethics
ommittee, and the study was carried out in accordance with
he Helsinki Declaration. Every patient provided written,
nformed consent.
nterventional procedure. All interventions were per-
ormed according to current standard guidelines, and the
nal interventional strategy was entirely left to the discre-
ion of the operator, aiming at a final residual stenosis
30% in the presence of Thrombolysis In Myocardial
nfarction (TIMI) flow grade 3. Periprocedural adjunctive
edications were used according to the operator’s decision.
ll patients were advised to maintain lifelong aspirin ther-
py. One-month clopidogrel treatment (75 mg/day) was
ecommended for patients treated in the pre-sirolimus
hase. For patients treated with SES, clopidogrel was
rescribed for three months, unless one of the following was
resent (in which case clopidogrel was maintained for at
east six months): multiple SES implantation (3 stents),
otal stented length 36 mm, chronic total occlusion,
ifurcations, or treatment of in-stent restenosis.
aterials. Sociodemographic variables included gender
nd age. Information on clinical variables (previous MI,
revious CABG, previous PCI, multivessel disease, hyper-
ension, hypercholesterolemia, diabetes mellitus, renal im-
airment, and smoking status) was sampled from the
edical records.
Type D personality was assessed with the 14-item Type
Personality Scale (DS14) (13). Type D personality
haracterizes those who tend to experience increased nega-
ive emotions and who do not express these emotions in
ocial interactions. The DS14 consists of the subscales
egative affectivity (NA) (e.g., “I often feel unhappy”) and
ocial inhibition (SI) (e.g., “I am a ‘closed’ person”). A score
10 on both subscales denotes those with a Type D
ersonality (13). The DS14 has adequate reliability with
ronbach’s alpha  0.88/0.86 and test-retest reliability r 
.72/0.82 for the NA and the SI subscales, respectively (13).
he validity of the subscales has been confirmed against
cales measuring similar constructs (13). The DS14 was
dministered to patients six months after PCI for logistic
easons. However, Type D personality has been shown to
xert a stable influence on outcome after invasive and
edical treatment compared with, for example, gender (14).
linical end point and definitions. The primary end point
as the occurrence of combined death (all-cause) or non-
atal MI during the nine months of follow-up. Myocardial
nfarction was diagnosed by a rise in the creatine kinase
CK) level to more than twice the upper normal limit with
n increased CK MB. Deaths (SES  14; bare  22)
ccurring before the administration of the DS14 were
xcluded from statistical analyses whereas MIs were in-
luded as prior MIs.
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September 1, 2004:997–1001 Type D and Prognosis After PCItatistical analysis. Discrete variables were compared with
he chi-square test and are presented as numbers and
ercentages. Continuous variables were compared with the
tudent t-test and are presented as means  SD. The
umulative incidence of death/MI was estimated according
o the Kaplan-Meier method. Differences between Type D
ersus non-Type D personality on outcome were compared
ith the log-rank test. The zero time point indicates the
ime of administration of the DS14 and will be referred to
s baseline in the remainder of this paper. Univariate and
ultivariate logistic regression analyses were used to exam-
ne the influence of demographics (gender and age), clinical
ariables (previous MI, previous CABG, previous PCI,
ultivessel disease, hypertension, hypercholesterolemia, di-
betes mellitus, renal impairment, and smoking status),
tent type (SES vs. bare), and personality type (Type D vs.
on-Type D) on death/MI. The multivariate analyses were
onducted in two steps. In the first step, all clinical variables
ere entered in a multivariate model and only those that
ere significant at p  0.05 were entered in the second step
ogether with gender, age, stent type, Type D personality,
nd the interaction term stent type  personality type. All
tatistical tests were two-tailed. A value of p  0.05 was
sed for all tests to indicate statistical significance. Odds
atios (ORs) with 95% confidence intervals (CIs) are re-
orted. All statistical analyses were performed using SPSS
ersion 11.5 (SPSS Inc., Chicago, Illinois).
ESULTS
atients with Type D personality were more likely to smoke
ompared with patients without Type D personality (37%
s. 29%, p  0.01). No other statistically significant differ-
nces were found between the two groups on baseline
haracteristics (Table 1). We also found no statistically
ignificant differences between patients with or without
ype D personality on treatment with beta-blockers, cal-
ium antagonists, nitrates, ACE inhibitors, statins, aspirin,
r clopidogrel (p  0.05).
At nine months’ follow-up, there were 20 events, i.e., 9
eaths and 11 MIs.
isk of a composite of death and MI. In a pooled sample
f patients regardless of stent type, patients with Type D
ersonality were at a cumulative increased risk of a compos-
te of death and MI at nine months compared with patients
ithout Type D personality: 5.6% versus 1.3% (OR 4.73;
5% CI 1.87 to 12.00) (Fig. 1). Previous CABG (OR 
.43) was also associated with an increased risk of death or
I in univariate analyses (Table 2).
ndependent predictors of outcome. In a multivariate
odel containing all clinical and demographic variables,
revious CABG (OR  4.00; 95% CI 1.25 to 12.78) was
he only variable that was significantly related to death or
I. Previous CABG was subsequently entered into a
ultivariate model together with Type D personality, gen-er, age, stent type (SES vs. bare), and the interaction term rtent type  personality type. Type D personality (OR 
.31; 95% CI 2.06 to 13.66) remained an independent
redictor of the incidence of death or MI adjusting for all
ther variables. Previous CABG (OR  3.03; 95% CI 1.04
o 8.87) was also associated with an increased risk of death
r MI. No association was found between stent type and
his end point (p 0.42), nor was the interaction term stent
ype  personality type statistically significant (p  0.11).
ISCUSSION
his is the first study to investigate the influence of
sychological risk factors on cardiac prognosis in post-PCI
atients in the new drug-eluting stent era. Type D person-
lity significantly increased the nine-month incidence of
eath or MI in patients treated with PCI. Type D person-
lity was shown to influence outcomes regardless of the
tent type used, i.e., conventional bare stents or last-
eneration SES, and established biomedical risk factors. It is
able 1. Baseline Characteristics (Six Months After PCI)
Type D
(n  254)
n (%)
Non-Type D
(n  621)
n (%) p Value
emographic factors
Female gender 77 (30) 169 (27) 0.35
Age, mean (SD) 61 (12) 63 (11) 0.07
tent type
SES 106 (42) 252 (41) 0.75
linical
Previous MI* 98 (39) 229 (37) 0.64
Previous CABG 28 (11) 73 (12) 0.76
Previous PCI 66 (26) 153 (25) 0.68
Multivessel disease 135 (53) 323 (52) 0.76
Hypertension† 104 (41) 235 (38) 0.39
Hypercholesterolemia‡ 214 (84) 495 (80) 0.12
Diabetes mellitus† 43 (17) 84 (14) 0.20
Renal impairment§ 83 (33) 182 (30) 0.37
Current smoking 95 (37) 178 (29) 0.01
Based on the judgment of the treating physician. †Present if being treated for the
ondition. ‡Total cholesterol levels 240 mg/dl or on lipid-lowering medication.
Indicated by creatinine clearance 60 ml/min. Based on self-report.
CABG  coronary artery bypass surgery prior to index event; MI  myocardial
nfarction; PCI  percutaneous coronary intervention prior to index event; SES 
irolimus-eluting stent.
igure 1. Nine months’ cumulative risk of death or myocardial infarction
fter percutaneous coronary intervention by personality type. OR  odds
atio; CI  confidence interval.
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Type D and Prognosis After PCI September 1, 2004:997–1001oteworthy that the risk associated with Type D personality
as on par with that of traditional biomedical risk factors.
Given the success of drug-eluting stents in reducing
estenosis, it seems timely to shift focus toward the identi-
cation of subgroups of patients at increased risk of mor-
ality. This may warrant expanding our focus to include
ore nonconventional risk factors, such as psychological
actors. Previous studies in patients following CABG have
hown that depression was associated with a more than
wo-fold increased risk of adverse outcome (4,5). In the
re-drug-eluting stent era, prior history of depression and
ital exhaustion have been shown to moderate the effects of
CI on outcome (6,7). In the current study, we found that
ype D personality was an independent predictor of death
r MI. This finding concurs with those of previous 5- to
0-year follow-up studies in the pre-drug-eluting stent era
n Type D personality (8–10). Surprisingly, however, in the
urrent study, Type D personality was related to adverse
utcome already at nine months. Taken together, these
esults indicate that subgroups of cardiac patients with a
articular psychological profile may not respond adequately
o treatment, and that for these subgroups some form of
sychosocial intervention is warranted.
Personality is considered to exert a stable influence on
ehavior, but this does not necessarily mean that the level of
istress of patients with a Type D personality cannot be
odified. However, psychosocial intervention studies tar-
eting negative emotions to decrease the risk of adverse
ardiovascular events have yielded mixed findings (15–18).
he extent to which patients with Type D personality may
xperience benefits from behavioral treatment needs to be
xamined in future intervention trials.
able 2. Predictors of Adverse Events at Nine Months
Univariate Analysis)
Death/MI (n  20)
OR (95% CI) p Value
sychological risk factors
Type D personality 4.73 (1.87–12.00) 0.001
emographic factors
Female gender 3.59 (0.83–15.59) 0.09
Age, mean (SD) 1.02 (0.98–1.06) 0.38
tent type
SES 1.46 (0.60–3.54) 0.41
linical risk factors
Previous MI* 1.70 (0.70–4.12) 0.24
Previous CABG 3.43 (1.29–9.13) 0.01
Previous PCI 1.63 (0.64–4.15) 0.32
Multi-vessel disease 1.12 (0.46–2.72) 0.81
Hypertension† 0.85 (0.34–2.15) 0.73
Hypercholesterolemia‡ 0.54 (0.20–1.42) 0.21
Diabetes mellitus† 1.49 (0.49–4.52) 0.48
Renal impairment§ 0.75 (0.27–2.09) 0.58
Smoking 1.19 (0.47–3.02) 0.71
Based on the judgment of the treating physician. †Present if being treated for the
ondition. ‡Total cholesterol levels 240 mg/dl or on lipid-lowering medication.
Indicated by creatinine clearance 60 ml/min. Based on self-report.
CI  confidence interval; OR  odds ratio. Other abbreviations as in Table 1.In the future, it also will be important to elucidate whichathophysiological mechanisms are responsible for the ad-
erse effect of Type D personality on cardiac prognosis.
reliminary evidence in patients with chronic heart failure
uggests that patients with Type D personality may have
ncreased levels of tumor necrosis factor (TNF)-alpha and
oluble TNF-alpha receptors compared with patients with-
ut Type D personality (19). These cytokines have been
ssociated with the pathogenesis and poor prognosis of
eart failure (20). In a study of healthy undergraduates, the
I and NA components of Type D personality were
ssociated with heightened blood pressure reactivity and
reater cortisol reactivity to stress (21). Further research into
he mechanisms responsible for the link between Type D
ersonality and cardiac prognosis is warranted in order to
ptimize treatment strategies.
The results of the current study should be interpreted
ith some caution. We had no information on left ventric-
lar dysfunction and New York Heart Association (NYHA)
unctional classification, which are known prognostic indi-
ators. Because of logistic reasons, the DS14 was adminis-
ered six months after PCI. This may have biased our
esults, as patients who died between zero and six months
id not have the opportunity to complete the DS14. On the
ther hand, Type D personality has been shown to exert a
table effect on outcome after invasive and conservative
reatment (14). Treatment type (SES vs. bare stent) was not
andomized given that implantation with SES has been
dopted as the treatment of choice for all PCI patients
eferred to our institution. However, patients were repre-
entative of the “real world” of interventional cardiology, as
o exclusion criteria were applied.
In summary, Type D personality was identified as an
ndependent predictor of adverse cardiac outcome in pa-
ients treated optimally with the latest advent in interven-
ional cardiology. The risk associated with Type D person-
lity was similar to that of traditional cardiovascular risk
actors. The DS14 could be used as a screening instrument
n routine clinical practice to optimize risk stratification in
atients with IHD. The scale is a valid and brief instrument
hat constitutes little burden to patients and to clinical
ractice.
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